Literature DB >> 24762486

Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.

Woo Young Kim, Hoon Yub Kim, Gil Soo Son, Jeoung Won Bae, Jae Bok Lee1.   

Abstract

BACKGROUND AND AIMS: Extrathyroidal extension (ETE) is one of the most important factors correlated to poor outcome of papillary thyroid carcinoma (PTC). However, the role of ETE in the prognosis of papillary thyroid microcarcinoma (PTMC) and the factor associated with ETE of PTMC are unclear. We investigated clinicopathological, immunohistochemical factors associated with ETE of PTMC to identify whether PTMC with ETE would have more adverse prognostic factors and higher risk for recurrence. SETTING AND
DESIGN: We enrolled patients performed thyroidectomy due to PTC between January 2003 and June 2008 and selected patients diagnosed with PTMC among them. We investigated numerous clinicopathological, immunohistochemical factors of selected patients.
MATERIALS AND METHODS: Data from 325 patients diagnosed with conventional PTMC by intraoperative frozen section and final pathology were recorded retrospectively. STATISTICAL ANALYSIS USED: A χ² test or an independent two-sample t-test, multiple logistic regression analysis, the Kaplan-Meier method, and log-rank test.
RESULTS: Thirty-four percent of patients (325 of 952) had PTMC on final pathology. Among them, the number of patients with and without ETE was 91 and 234, respectively. On both univariate and multivariate analysis; ETE of PTMC correlated with size (P < 0.001); tumor, node, and metastasis (TNM) staging (P = 0.001); multifocality (P = 0.001); lymph node metastasis (P < 0.001); radioactive iodine (RAI) therapy (P = 0.001); and recurrence (P = 0.037).
CONCLUSIONS: ETE of conventional PTMC is associated with size, multifocality, lymph node metastasis, and recurrence. More extensive surgery should be considered for patients having ETE identified by intraoperative frozen sections, preoperative imaging, and intraoperative finding and other high risk factors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24762486     DOI: 10.4103/0973-1482.131366

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

1.  Intraoperative frozen section for the evaluation of extrathyroidal extension in papillary thyroid cancer.

Authors:  Young Min Park; Soo-Geun Wang; Jin Young Goh; Dong Hoon Shin; In-Ju Kim; Byung-Joo Lee
Journal:  World J Surg       Date:  2015-01       Impact factor: 3.352

2.  Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?

Authors:  Victoria Harries; Laura Y Wang; Marlena McGill; Bin Xu; R Michael Tuttle; Richard J Wong; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Snehal G Patel; Ian Ganly
Journal:  Surgery       Date:  2019-09-09       Impact factor: 3.982

3.  Iodine Maps from Dual-Energy CT to Predict Extrathyroidal Extension and Recurrence in Papillary Thyroid Cancer Based on a Radiomics Approach.

Authors:  X-Q Xu; Y Zhou; G-Y Su; X-W Tao; Y-Q Ge; Y Si; M-P Shen; F-Y Wu
Journal:  AJNR Am J Neuroradiol       Date:  2022-04-14       Impact factor: 3.825

4.  Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer.

Authors:  Wei Sun; Xiabin Lan; Zhihong Wang; Wenwu Dong; Liang He; Ting Zhang; Hao Zhang
Journal:  Med Oncol       Date:  2016-08-10       Impact factor: 3.064

5.  Soft tissue invasion of papillary thyroid carcinoma.

Authors:  Jen-Der Lin; Chuen Hsueh; Tzu-Chieh Chao
Journal:  Clin Exp Metastasis       Date:  2016-05-06       Impact factor: 5.150

6.  The high degree of similarity in histopathological and clinical characteristics between radiogenic and sporadic papillary thyroid microcarcinomas in young patients.

Authors:  Tetiana Bogdanova; Serhii Chernyshov; Liudmyla Zurnadzhy; Tatiana I Rogounovitch; Norisato Mitsutake; Mykola Tronko; Masahiro Ito; Michael Bolgov; Sergii Masiuk; Shunichi Yamashita; Vladimir A Saenko
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.